TRADITIONAL POSTER - ismrm

Poster Sessions
fMRI Fluctuations & Connectivity
Hall B Monday 14:00-16:00
1167. Comparison of BOLD Response Modulation During Pain Stimulation and Resting-State Conditions
Under Intravenous (0.2 Mg/70kg) or Sublingual (2 Mg) Buprenorphine Treatment
Jaymin Upadhyay 1,2 , Julie Anderson 1,2 , Adam J. Schwarz 1,3 , Richard Baumgartner 1,4 , Alexandre
Coimbra 1,5 , Lauren Nutile 1,2 , James Bishop 1,2 , Ed George 1,6 , Brigitte Robertson 1,7 , Smriti Iyengar 1,3 , David
Bleakman 1,3 , Richard Hargreaves 1,5 , Lino Becerra 1,2 , David Borsook 1,2
1 Imaging Consortium for Drug Development, Harvard Medical School, Belmont, MA, United States; 2 P.A.I.N. Group; Brain Imaging
Center, McLean Hospital, Belmont, MA, United States; 3 Lilly Research Department, Eli Lilly and Company, Indianapolis, IN, United
States; 4 Biometrics Research Department, Merck Research Laboratories, Rahway, NJ, United States; 5 Imaging Department, Merck
Research Laboratories, West Point, PA, United States; 6 Department of Anesthesiology and Critical Care, Massachusetts General
Hospital, Harvard Medical School, Boston, MA, United States; 7 Sepracor, Inc., Marlborough, MA, United States
Buprenorphine is commonly prescribed to treat pain. We implemented blood oxygenated-level dependent (BOLD) functional MRI to characterize and
compare the effects of 2.0 mg (sublingual), 0.1 mg/70kg (intravenous) and 0.2 mg/70kg (intravenous) doses of buprenorphine on the central nervous system
during pain processing and during the resting state. During pain processing, the 2.0 mg (sublingual) and 0.2 mg/70kg (intravenous) doses significantly
(p